| Imjudo (tremelimumab) / AstraZeneca, Pfizer |
| Completed | 2 | 18 | RoW | Durvalumab,Tremelimumab, Experimental group | Seoul National University Hospital, Korean Cancer Study Group | HNSCC, Head and Neck Neoplasms | 02/19 | 06/21 | | |
| Completed | 2 | 32 | RoW | durvalumab + tremelimumab | Seoul National University Hospital | Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC | 02/18 | 11/19 | | |
NCT02879162: Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours |
|
|
| Active, not recruiting | 2 | 140 | Canada | Durvalumab, Tremelimumab | Canadian Cancer Trials Group, AstraZeneca | Advanced Rare Tumours | 06/22 | 12/22 | | |
| Completed | 2 | 103 | Europe | Durvalumab and Tremelimumab, Doxorubicin | AIO-Studien-gGmbH, AstraZeneca | Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma | 08/22 | 08/22 | | |
NCT03015129: A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer |
|
|
| Completed | 2 | 80 | US | Durvalumab, Tremelimumab | Memorial Sloan Kettering Cancer Center | Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma, Endometrial Cancer Recurrent, Endometrial Carcinoma, Recurrent | 12/22 | 12/22 | | |
NCT02815995: Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes |
|
|
| Completed | 2 | 56 | US | Durvalumab, Tremelimumab | M.D. Anderson Cancer Center, MedImmune LLC | Advanced and/or Metastatic Sarcoma | 06/24 | 06/24 | | |
NCT02643303: A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers |
|
|
| Completed | 1/2 | 58 | US | Durvalumab, MEDI4736, Imfinzi®, Tremelimumab, Poly-ICLC, Hiltonol® | Ludwig Institute for Cancer Research, MedImmune LLC, Cancer Research Institute, New York City | Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor | 02/22 | 02/22 | | |
NEXIS, NCT03116529: Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma |
|
|
| Active, not recruiting | 1/2 | 22 | US | Combination Radiation, Immunotherapy, Surgery | University of Maryland, Baltimore, AstraZeneca, University of Arizona, West Penn Allegheny Health System | Soft Tissue Sarcoma | 06/32 | 06/37 | | |
